Authors' recommendations: There was a dearth of comparative evidence describing the use of the eFlow® nebuliser device for the treatment of cystic fibrosis patients. Both of the included studies reported shorter nebulisation times in comparison to conventional compressor nebulisers, which should translate into greater patient compliance and therefore improved therapeutic outcomes. However, this conclusion cannot be supported by the evidence included for assessment in this summary. Studies with long-term endpoints are required to confirm this speculation. Consideration should also be given to the large number of other nebulisation devices that are coming onto the market, including the eFlow®. In addition, the safety and effectiveness of the device needs to be considered when different pharmaceuticals are used. Although only low level of evidence was available for inclusion in this assessment, the eFlow® device shows potential for improved therapeutic outcomes due to the associated shorter nebulisation times. Patient compliance with medication may play a role in the uptake of this technology. There are a number of clinical studies either recently completed or commenced which may provide more detailed information regarding the effectiveness of this device. HealthPACT will await further feedback from clinicians regarding the effectiveness and expected uptake of this device.

Project Status: Completed

Year Published: 2010

URL for published report: Not Available

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Australia

Organisation Name: Adelaide Health Technology Assessment

Contact Address: School of Public Health, Mail Drop 545, University of Adelaide, Adelaide SA 5005, AUSTRALIA, Tel: +61 8 8313 4617

Contact Name: ahta@adelaide.edu.au

Contact Email: ahta@adelaide.edu.au

Copyright: Adelaide Health Technology Assessment (AHTA)